Australia markets closed

Amplia Therapeutics Limited (ATX.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.0610-0.0030 (-4.69%)
At close: 04:10PM AEST
Full screen
Previous close0.0640
Open0.0640
Bid0.0610 x 0
Ask0.0640 x 0
Day's range0.0610 - 0.0640
52-week range0.0550 - 0.0940
Volume630,862
Avg. volume273,246
Market cap16.568M
Beta (5Y monthly)0.65
PE ratio (TTM)N/A
EPS (TTM)-0.0200
Earnings date30 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Simply Wall St.

    Allan Moss Buys 40% More Amplia Therapeutics Shares

    Investors who take an interest in Amplia Therapeutics Limited ( ASX:ATX ) should definitely note that insider Allan...

  • PR Newswire

    FDA CLEARANCE OF AMPLIA'S IND FOR PANCREATIC CANCER TRIAL IN US

    Amplia Therapeutics Limited (ASX: ATX), ("Amplia" or the "Company"), is pleased to announce that the US FDA have cleared Amplia's IND application for a trial of Amplia's best-in-class focal adhesion kinase (FAK) inhibitor narmafotinib in pancreatic cancer. The proposed trial will explore the safety, tolerability and efficacy of a combination of narmafotinib with the chemotherapy regime FOLFIRINOX.

  • PR Newswire

    AACR OVARIAN CANCER CONFERENCE PRESENTATION

    Amplia Therapeutics Limited (ASX: ATX), ("Amplia" or the "Company") is pleased to announce that a poster, detailing a series of preclinical studies in ovarian cancer models, was presented at the American Association for Cancer Research (AACR) Special Conference In Cancer Research: Ovarian Cancer meeting, held in Boston, USA over the weekend. The poster describes research with narmafotinib (AMP945) conducted by the company's collaborators at the University of California, San Diego (UCSD), and was